452 results on '"Adès L"'
Search Results
2. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
3. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
4. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
5. POS0954 CLINICAL FEATURES AND GENOMIC LANDSCAPE OF MYELOPROLIFERATIVE NEOPLASM (MPN) PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASES
6. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
7. Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
8. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
9. P057 - Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION
10. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
11. O08 - GERMLINE CHEK2 MUTATED MDS PATIENTS
12. IS01 - ATTEMPTS TO IMPROVE HYPOMETHYLATING AGENT-BASED REGIMENS: A TEN-YEAR EXPERIENCE
13. Dermatose par infiltrat à cellules dendritiques plasmacytoïdes ou indéterminées matures chez des patients atteints d’hémopathie myéloïde, une étude de 14 cas
14. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
15. Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML
16. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
17. P727: NK-CELL IMMUNOEDITING BY MESENCHYMAL STROMAL CELLS IN MDS
18. AB0044 REDUCED PERIPHERAL BLOOD MYELOID CELLS IN PATIENTS WITH VEXAS SYNDROME
19. Utility of next-generation sequencing technologies for the efficient genetic resolution of haematological disorders
20. O24 - Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: APR 246 PLUS AZACITIDINE (AZA) IN TP53 MUTATED (M) MDS AND AML. LONG TERM FOLLOW UP OF PHASE 2 STUDY BY THE GFM
21. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS
22. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
23. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
24. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
25. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
26. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
27. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
28. ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
29. NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia
30. Genotype and clinical care correlations in craniosynostosis: Findings from a cohort of 630 Australian and New Zealand patients
31. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
32. The new Ghent criteria for Marfan syndrome: what do they change?
33. PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
34. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
35. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission
36. Pathogenic FBN1 Mutations in 146 Adults Not Meeting Clinical Diagnostic Criteria for Marfan Syndrome: Further Delineation of Type 1 Fibrillinopathies and Focus on Patients With an Isolated Major Criterion
37. Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
38. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
39. FBN1, TGFBR1, and the Marfan-Craniosynostosis/Mental Retardation Disorders Revisited
40. Histopathology and Fibrillin-1 Distribution in Severe Early Onset Marfan Syndrome
41. The Hunter–McAlpine syndrome results from duplication 5q35–qter
42. PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL
43. Manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques : effet de l’azacitidine sur les différentes populations immunitaires
44. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems
45. Caractéristiques phénotypiques et mutationnelles des maladies auto-immunes et inflammatoires (MAI) associées aux néoplasies myéloprolifératives (NMP)
46. A craniosynostosis massively parallel sequencing panel study in 309 Australian and New Zealand patients: findings and recommendations
47. Infiltrat myéloïde clonal identifié par next generation sequencing dans les lésions cutanées associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques
48. P114 Treatment of lower risk MDS with del 5q by lenalidomide (LEN), with or without G-CSF: current results of the French Patient Named Program (ATU)
49. P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts)
50. P118 The capacity of the hypomethylating agents azacytidine and decitabine to induce apoptosis and cell cycle arrest depends on the activation of the DNA-damage response pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.